



IFW

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Wilfried Braje et al.	)	Examiner:	Unknown
		)		
Serial No.:	10/552,842	)	Group Art Unit:	Unknown
		)		
Filed:	October 11, 2005	)	Confirmation No.:	4358
		)		
For: N-[(Piperazinyl)hetaryl]arylsulfonamide		)	Atty. Dkt.:	ABB10043P00013US
compounds with affinity for the		)		
Dopamine D <sub>3</sub> receptor		)		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. The literature references and foreign patent references are enclosed. Entry into the record is respectfully requested.

Respectfully submitted



By Martin L. Katz  
Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER  
Citigroup Center, Suite 3800  
500 West Madison Street  
Chicago, Illinois 60661  
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on **September 22, 2006**

Stephanie Frain  
Stephanie Frain



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/552,842
				Filing Date	10/11/2005 (In'l. Filing date 04/13/2004)
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket No.	ABB10043P00013US

#### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

#### FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 2004/058265	07/15/2004	BioFocus PLC		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/552,842
				Filing Date	10/11/2005 (Int'l. Filing date 04/13/2004)
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No.	ABB10043P00013US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		STEVEN M BROMIDGE ET AL. "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT <sub>6</sub> Receptor Antagonist" J. Med. Chem 1999, 42, pp. 202-205	
		BERNARD WILLECOMME "Recherches Dans La Serie De the Piperazine" Annales de Chimie, No. 6, 1969 (4) p. 405-28	
		STEVEN M BROMIDGE ET AL. "Novel (4-Piperazin-1-ylquinolin-6-yl) Arylsulfonamides with High Affinity and Selectivity for the 5-HT <sub>6</sub> Receptor" Bioorganic & Medicinal Chemistry Letters 11 (2001) pp. 2843-46	
		Chemical Abstract Service, Database Chemcats, Columbus, Ohio, US, Document No. XP-002294060, Order No. 4L-392S, Interchim Intermediates, Montlucon, France 07/09/2002	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.